Intranasal COVID-19 vaccine candidate generates robust immune response

BOSTON — Two doses of an experimental live-attenuated intranasal COVID-19 vaccine generated a robust immune response, according to phase one data presented at IDWeek.
“Live-attenuated virus vaccines are a modality that have been around for decades. The trial that [these data are] from is a first in-human clinical trial that was a placebo-controlled dose escalation trial using CoviLiv that is delivered intranasally,” Johanna K. Kaufmann, PhD, executive vice president of oncology and immunology at Codagenix Inc., said during an IDWeek press conference.
“In contrast to the

BOSTON — Two doses of an experimental live-attenuated intranasal COVID-19 vaccine generated a robust immune response, according to phase one data presented at IDWeek.
“Live-attenuated virus vaccines are a modality that have been around for decades. The trial that [these data are] from is a first in-human clinical trial that was a placebo-controlled dose escalation trial using CoviLiv that is delivered intranasally,” Johanna K. Kaufmann, PhD, executive vice president of oncology and immunology at Codagenix Inc., said during an IDWeek press conference.
“In contrast to the